Literature DB >> 25048863

Prostate cancer: Predicting response to androgen receptor signalling inhibition.

Christopher P Evans1, Primo N Lara2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25048863     DOI： 10.1038/nrurol.2014.179

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN： 1759-4812            Impact factor:   14.432


× No keyword cloud information.
  7 in total

1.  Effects of abiraterone acetate on androgen signaling in castrate-resistant prostate cancer in bone.

Authors:  Eleni Efstathiou; Mark Titus; Dimitra Tsavachidou; Vassiliki Tzelepi; Sijin Wen; Anh Hoang; Arturo Molina; Nicole Chieffo; Lisa A Smith; Maria Karlou; Patricia Troncoso; Christopher J Logothetis
Journal:  J Clin Oncol       Date:  2011-12-19       Impact factor: 44.544

2.  Increased survival with enzalutamide in prostate cancer after chemotherapy.

Authors:  Howard I Scher; Karim Fizazi; Fred Saad; Mary-Ellen Taplin; Cora N Sternberg; Kurt Miller; Ronald de Wit; Peter Mulders; Kim N Chi; Neal D Shore; Andrew J Armstrong; Thomas W Flaig; Aude Fléchon; Paul Mainwaring; Mark Fleming; John D Hainsworth; Mohammad Hirmand; Bryan Selby; Lynn Seely; Johann S de Bono
Journal:  N Engl J Med       Date:  2012-08-15       Impact factor: 91.245

Review 3.  Blood-based analyses of cancer: circulating tumor cells and circulating tumor DNA.

Authors:  Daniel A Haber; Victor E Velculescu
Journal:  Cancer Discov       Date:  2014-05-06       Impact factor: 39.397

4.  Niclosamide inhibits androgen receptor variants expression and overcomes enzalutamide resistance in castration-resistant prostate cancer.

Authors:  Chengfei Liu; Wei Lou; Yezi Zhu; Nagalakshmi Nadiminty; Chad T Schwartz; Christopher P Evans; Allen C Gao
Journal:  Clin Cancer Res       Date:  2014-04-16       Impact factor: 12.531

5.  NF-κB2/p52 induces resistance to enzalutamide in prostate cancer: role of androgen receptor and its variants.

Authors:  Nagalakshmi Nadiminty; Ramakumar Tummala; Chengfei Liu; Joy Yang; Wei Lou; Christopher P Evans; Allen C Gao
Journal:  Mol Cancer Ther       Date:  2013-05-22       Impact factor: 6.261

6.  Molecular characterization of enzalutamide-treated bone metastatic castration-resistant prostate cancer.

Authors:  Eleni Efstathiou; Mark Titus; Sijin Wen; Anh Hoang; Maria Karlou; Robynne Ashe; Shi Ming Tu; Ana Aparicio; Patricia Troncoso; James Mohler; Christopher J Logothetis
Journal:  Eur Urol       Date:  2014-05-29       Impact factor: 20.096

7.  Targeting autophagy overcomes Enzalutamide resistance in castration-resistant prostate cancer cells and improves therapeutic response in a xenograft model.

Authors:  H G Nguyen; J C Yang; H-J Kung; X-B Shi; D Tilki; P N Lara; R W DeVere White; A C Gao; C P Evans
Journal:  Oncogene       Date:  2014-03-24       Impact factor: 9.867
  7 in total
  1 in total

1.  The anti-proliferative effects of enterolactone in prostate cancer cells: evidence for the role of DNA licencing genes, mi-R106b cluster expression, and PTEN dosage.

Authors:  Mark J McCann; Ian R Rowland; Nicole C Roy
Journal:  Nutrients       Date:  2014-11-03       Impact factor: 5.717
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.